Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Part of paid clinical trials in Miami, Florida.

Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Study ID
NCT07159750
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CGRP antibody or gepant — DRUG
    Patients will start anti-CGRP or its receptor antibody or gepants

Study Details

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Key Dates

Start date
Jan 2, 2024
Status verified
Aug 2025
Primary completion
Jan 31, 2026
Completion
Jan 31, 2026

Study Design

Enrollment
700 participants (estimated)

Arms

  • Arm: Migraine Patients
    Migraine patients who initiate a CGRP-targeted treatment

Primary Outcome Measure

Change in Monthly Headache Days and Monthly Migraine Days [ Time Frame: Through study completion, an average of 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Miami, Miller School of MedicineMiamiFlorida33136
Teshamae S Monteith
[email protected]
305-243-2010

Find similar trials in Miami, FL

By condition
Migraine
By specialty
Neurology
By research site
University of Miami, Miller School of Medicine· Miami, FL

Related Studies